Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis

Tahreem A. Mir, Ashvini K. Reddy, Bryn M. Burkholder, James Walsh, Amde Selassie Shifera, Irfan R. Khan, Jennifer E. Thorne

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose To describe the incidence rates of visual loss and ocular complications in patients with retinal vasculitis (RV). Design Retrospective cohort study. Methods Clinical data were collected for 96 patients (175 eyes) diagnosed with RV from 2003 to 2013. Main outcome measures included rates of visual loss and ocular complications. Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed. Results Over a median follow-up of 44 months (range: 1–153 months), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY, 95% confidence interval [CI], 0.09/EY to 0.18/EY) and to 20/200 or worse was 0.06/EY (95% CI, 0.04/EY to 0.08/EY). The most common complications were cataract (0.31/EY), epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY). Patients with a relapsing course (median number of relapses = 1, range: 1–6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95% CI, 0.88–4.90, P =.09) and 20/200 or worse (OR = 2.49; 95% CI, 0.98–6.30, P =.05). Immunosuppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66–0.94, P =.01 and OR = 0.73; 95% CI, 0.57–0.93, P =.01 for the 20/50 or worse and 20/200 or worse thresholds, respectively). Conclusions Rates of visual loss and complications among patients with RV were similar to reported rates in noninfectious uveitides. Treatment with immunosuppressive drugs lowered the risk of visual loss. A relapsing course suggested an increased risk for visual loss but was not statistically significant, perhaps owing to low numbers of recurrences.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume179
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Retinal Vasculitis
Confidence Intervals
Incidence
Odds Ratio
Immunosuppressive Agents
Epiretinal Membrane
Recurrence
Macular Edema
Uveitis
Cataract
Cohort Studies
Retrospective Studies
Outcome Assessment (Health Care)
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mir, T. A., Reddy, A. K., Burkholder, B. M., Walsh, J., Shifera, A. S., Khan, I. R., & Thorne, J. E. (2017). Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis. American Journal of Ophthalmology, 179, 171-178. https://doi.org/10.1016/j.ajo.2017.05.007

Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis. / Mir, Tahreem A.; Reddy, Ashvini K.; Burkholder, Bryn M.; Walsh, James; Shifera, Amde Selassie; Khan, Irfan R.; Thorne, Jennifer E.

In: American Journal of Ophthalmology, Vol. 179, 01.07.2017, p. 171-178.

Research output: Contribution to journalArticle

Mir, TA, Reddy, AK, Burkholder, BM, Walsh, J, Shifera, AS, Khan, IR & Thorne, JE 2017, 'Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis', American Journal of Ophthalmology, vol. 179, pp. 171-178. https://doi.org/10.1016/j.ajo.2017.05.007
Mir, Tahreem A. ; Reddy, Ashvini K. ; Burkholder, Bryn M. ; Walsh, James ; Shifera, Amde Selassie ; Khan, Irfan R. ; Thorne, Jennifer E. / Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis. In: American Journal of Ophthalmology. 2017 ; Vol. 179. pp. 171-178.
@article{0d77f3f704a94e028f7b11a4624462f5,
title = "Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis",
abstract = "Purpose To describe the incidence rates of visual loss and ocular complications in patients with retinal vasculitis (RV). Design Retrospective cohort study. Methods Clinical data were collected for 96 patients (175 eyes) diagnosed with RV from 2003 to 2013. Main outcome measures included rates of visual loss and ocular complications. Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed. Results Over a median follow-up of 44 months (range: 1–153 months), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY, 95{\%} confidence interval [CI], 0.09/EY to 0.18/EY) and to 20/200 or worse was 0.06/EY (95{\%} CI, 0.04/EY to 0.08/EY). The most common complications were cataract (0.31/EY), epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY). Patients with a relapsing course (median number of relapses = 1, range: 1–6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95{\%} CI, 0.88–4.90, P =.09) and 20/200 or worse (OR = 2.49; 95{\%} CI, 0.98–6.30, P =.05). Immunosuppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95{\%} CI, 0.66–0.94, P =.01 and OR = 0.73; 95{\%} CI, 0.57–0.93, P =.01 for the 20/50 or worse and 20/200 or worse thresholds, respectively). Conclusions Rates of visual loss and complications among patients with RV were similar to reported rates in noninfectious uveitides. Treatment with immunosuppressive drugs lowered the risk of visual loss. A relapsing course suggested an increased risk for visual loss but was not statistically significant, perhaps owing to low numbers of recurrences.",
author = "Mir, {Tahreem A.} and Reddy, {Ashvini K.} and Burkholder, {Bryn M.} and James Walsh and Shifera, {Amde Selassie} and Khan, {Irfan R.} and Thorne, {Jennifer E.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.ajo.2017.05.007",
language = "English (US)",
volume = "179",
pages = "171--178",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Clinical Features and Incidence Rates of Ocular Complications in Patients With Retinal Vasculitis

AU - Mir, Tahreem A.

AU - Reddy, Ashvini K.

AU - Burkholder, Bryn M.

AU - Walsh, James

AU - Shifera, Amde Selassie

AU - Khan, Irfan R.

AU - Thorne, Jennifer E.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose To describe the incidence rates of visual loss and ocular complications in patients with retinal vasculitis (RV). Design Retrospective cohort study. Methods Clinical data were collected for 96 patients (175 eyes) diagnosed with RV from 2003 to 2013. Main outcome measures included rates of visual loss and ocular complications. Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed. Results Over a median follow-up of 44 months (range: 1–153 months), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY, 95% confidence interval [CI], 0.09/EY to 0.18/EY) and to 20/200 or worse was 0.06/EY (95% CI, 0.04/EY to 0.08/EY). The most common complications were cataract (0.31/EY), epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY). Patients with a relapsing course (median number of relapses = 1, range: 1–6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95% CI, 0.88–4.90, P =.09) and 20/200 or worse (OR = 2.49; 95% CI, 0.98–6.30, P =.05). Immunosuppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66–0.94, P =.01 and OR = 0.73; 95% CI, 0.57–0.93, P =.01 for the 20/50 or worse and 20/200 or worse thresholds, respectively). Conclusions Rates of visual loss and complications among patients with RV were similar to reported rates in noninfectious uveitides. Treatment with immunosuppressive drugs lowered the risk of visual loss. A relapsing course suggested an increased risk for visual loss but was not statistically significant, perhaps owing to low numbers of recurrences.

AB - Purpose To describe the incidence rates of visual loss and ocular complications in patients with retinal vasculitis (RV). Design Retrospective cohort study. Methods Clinical data were collected for 96 patients (175 eyes) diagnosed with RV from 2003 to 2013. Main outcome measures included rates of visual loss and ocular complications. Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed. Results Over a median follow-up of 44 months (range: 1–153 months), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY, 95% confidence interval [CI], 0.09/EY to 0.18/EY) and to 20/200 or worse was 0.06/EY (95% CI, 0.04/EY to 0.08/EY). The most common complications were cataract (0.31/EY), epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY). Patients with a relapsing course (median number of relapses = 1, range: 1–6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95% CI, 0.88–4.90, P =.09) and 20/200 or worse (OR = 2.49; 95% CI, 0.98–6.30, P =.05). Immunosuppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66–0.94, P =.01 and OR = 0.73; 95% CI, 0.57–0.93, P =.01 for the 20/50 or worse and 20/200 or worse thresholds, respectively). Conclusions Rates of visual loss and complications among patients with RV were similar to reported rates in noninfectious uveitides. Treatment with immunosuppressive drugs lowered the risk of visual loss. A relapsing course suggested an increased risk for visual loss but was not statistically significant, perhaps owing to low numbers of recurrences.

UR - http://www.scopus.com/inward/record.url?scp=85019738304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019738304&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2017.05.007

DO - 10.1016/j.ajo.2017.05.007

M3 - Article

C2 - 28501390

AN - SCOPUS:85019738304

VL - 179

SP - 171

EP - 178

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -